Gene therapy: Future therapy for erectile dysfunction

Current Urology Reports

Volumn 2, Issue 6, 2001, Pages 480-487

  Schenk, Gregory ^a   Melman, Arnold ^a   Christ, George J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cavernous Nerve; Erectile Dysfunction; Gene Therapy; Intracavernous Injection; Priapism

Indexed keywords

GENE THERAPY; GENETICS; HUMAN; IMPOTENCE; MALE; PATHOPHYSIOLOGY; REVIEW;

GENE THERAPY; HUMANS; IMPOTENCE; MALE;

EID: 0035553633     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-001-0043-7     Document Type: Article

References (25)

1. NIH Consensus Development Panel on Impotence: NIH Consensus Conference. Impotence. JAMA 1993, 270:83–90. DOI: 10.1001/jama.270.1.83
2. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR: Impact of erectile dysfunction on quality of life: patient and partner perspec-tives. Int J Impot Res 2000, 12(suppl 4):S144-S146. DOI: 10.1038/sj.ijir.3900594
3. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000, 12(suppl 4):S6-S11. DOI: 10.1038/sj.ijir.3900567
4. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results from the Massachusetts Male Aging Study. J Urol 1994, 151:54–61.
5. Melman A, Gingell JC: The epidemiology and pathophysiol-ogy of erectile dysfunction. J Urol 1999, 161:5–11. DOI: 10.1016/S0022-5347(01)62045-7
6. Christ GJ: Gap junctions and ion channels: relevance to erec-tile dysfunction. Int J Impot Res 2000, 12(suppl 4):S15-S25. DOI: 10.1038/sj.ijir.3900573
7. Andersson KE, Wagner G: Physiology of penile erection. Physiol Rev 1995, 75:191–225.
8. Lue TF: Drug therapy: erectile dysfunction. N Engl J Med 2000, 342:1802–1813. An authoritative review on erectile physiology and dysfunction and a “state-of-the-art” review of all forms of pharmacotherapy for the treat-ment of erectile dysfunction. DOI: 10.1056/NEJM200006153422407
9. Christ GJ: A new frontier: Gene therapy for erectile dysfunc-tion. In Current Concepts in the Treatment of Erectile Dysfunction. Edited by Morales A. London: Martin Dunitz Publishers; 1998:209–230. The first review of the practices and principles supporting the application of gene therapy to the treatment of erectile dysfunction.
10. Christ GJ: Gene therapy: future strategies and therapies. Drugs of Today 2000, 36:175–184.
11. Garban H, Marquez D, Magee T, et al.: Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy to the treatment of erectile dysfunction. Biol Reprod 1997, 56(4):954–963. The first publication documenting the potential utility of gene therapy to the treatment of erectile dysfunction. DOI: 10.1095/biolreprod56.4.954
12. Christ GJ: The penis as a vascular organ: the importance of corporal smooth muscle tone in the control of erection. Urol Clin North Am 1995, 22:727–745.
13. Birder L, Kanai J, Tirney S, et al.: Direct measurement of basal nitric oxide release with a porphyrinic microsensor following inducible nitric oxide synthase gene therapy. J Urol 1998, 159:95. DOI: 10.1016/S0022-5347(01)64022-9
14. Huard J, Tirney S, Mattes CE, et al.: Nitric oxide synthase therapy for erectile dysfunction: comparison between plasmid, adenovirus, and adenovirus-transduced myoblast vectors. J Urol 1998, 159:90. DOI: 10.1016/S0022-5347(01)64020-5
15. Rehman J, Christ GJ, Melman A, et al.: Enhancement of the physiologic erectile function with nitric oxide synthase gene therapy. J Urol 1997; 157:782A. DOI: 10.1016/S0022-5347(01)64953-X
16. Wessels H, Williams SK: Endothelial cell transplantation into the corpus cavernosum: basis for efficient gene therapy for erectile dysfunction. J Urol 1998, 159:92.
17. Wessels H, Williams SK: Transplantation of microvessel endothelial cells into the corpus cavernosum: Applications for gene therapy. Int J Impot Res 1998, 10:S7.
18. Champion HC, Bivalacqua TJ, Hyman AL, et al.: Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci 1999, 96:11648–11652. DOI: 10.1073/pnas.96.20.11648
19. Burchardt M, Burchardt T, Chen M-W, et al.: Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. Biol Reprod 1999, 60:398–404. DOI: 10.1095/biolreprod60.2.398
20. Rogers RS, Graziottin TM, Gholami S, et al.: Intracavernosal VEGF and AAV-VEGF gene therapy prevents ED in a rat model of venous leakage impotence. J Urol 2001, 165(5):221.
21. Bakircioglu ME, Lin C-S, Fan P, et al.: The effect of adeno-associ-ated virus mediated brain derived neurotrophic factor in an ani-mal model of neurogenic impotence. J Urol 2001, 165:2103–2109. DOI: 10.1016/S0022-5347(05)66302-1
22. Christ GJ, Rehman J, Day N, et al.: Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alter-ations in penile function. Am J Physiol 1998, 275:H600-H608. This article details the rationale and utility of the first application of ion channels for gene therapy in smooth muscle.
23. Sato Y, Day N, Melman A, Christ GJ: Gene therapy with maxi-K+ channels restores diminished erectile response in older animals during electrical stimulation of the medial preoptic area (MPOA). J Urol 2000, 163(4):198.
24. Sato Y, Day N, Valcic M, et al.: The effects of gene therapy with maxi-K+ channels: apomorphine-evoked increases in intrac-avernous pressure in the awake rat. J Urol 2001, 165(5):220.
25. Christ GJ, Smith WL, Santizo C, et al.: K+ channel gene therapy is associated with increased nerve-stimulated intracavernous pressure (ICP) responses despite diminished neuronal innervation following 3–4 months of experimental diabetes in rats. FASEB J 1999:A192.